Side-by-side · Research reference
CardiogenvsIpamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED5/46 cited
BPhase 1HUMAN-REVIEWED21/57 cited
Cardiogen
Bioregulator · Cardiac
CardiacTissue target
Gene regulationMechanism
AnimalEvidence level
SQ · Variable protocols
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Cardiogen
Ipamorelin
Primary target
Cardiovascular cell gene expressionKhavinson 2022
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
Pathway
Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
Downstream effect
Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Feedback intact?
Presumed — peptide bioregulators act via gene regulation, not receptor agonism
Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002
Origin
Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
Antibody development
—
Not reported in short-term studies
02Dosage Protocols
Parameter
Cardiogen
Ipamorelin
Standard dose
Variable — typically 10–20 mg per course
No standardised human protocol; animal-derived dosing.
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
Frequency
Intermittent courses — 10–20 days, repeated periodically
Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
Evidence basis
Animal models / mechanistic studies
No Phase 1+ human trials in PubMed.
Phase 1 + clinical practiceRaun 1998Sigalos 2018
Route
Subcutaneous injection
—
Duration
10–20 day courses, repeated 2–4× per year
Russian geriatric protocols; unclear extrapolation to general populations.
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
Lower / starter dose
—
100 mcg per dose
Reconstitution
—
Bacteriostatic water; typical 2 mL per 5 mg vial
Timing
—
Pre-sleep + fasted preferred; 30 min away from food
04Side Effects & Safety
Parameter
Cardiogen
Ipamorelin
Injection site reactions
Mild erythema, induration (presumed)
—
Systemic adverse events
No documented serious AEs in available literature
Very limited safety data; no rigorous pharmacovigilance.
—
Immunogenicity
Unknown — no antibody development studies published
—
Long-term safety
Unknown — no extended human trials indexed in PubMed
—
Hunger
—
Mild appetite increase via ghrelin-receptor crosstalk
Injection site reaction
—
Mild irritation possible
GH excess (overdose)
—
Joint pain, edema, insulin resistance
IGF-1 elevation
—
Dose-dependent; monitor with chronic high-dose use
Cancer risk
—
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
Pregnancy / OB
—
Avoid
Absolute Contraindications
Cardiogen
- ·Active malignancy (theoretical peptide growth factor concern)
- ·Hypersensitivity to peptide components
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Cardiogen
- ·Acute cardiac events (no safety data in acute MI, unstable angina)
- ·Pregnancy / lactation (no reproductive toxicity data)
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
05Administration Protocol
Parameter
Cardiogen
Ipamorelin
1. Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
3. Timing
Variable — often evening injection. No established circadian preference.
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
4. Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
5. Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Cardiogen
+ Thymalin
ModerateKhavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.
- Cardiogen
- 10–20 mg SQ · 10–20 day course
- Thymalin
- 10–30 mg IM · concurrent or sequential courses
- Frequency
- 2–4 courses per year
- Primary benefit
- Multi-system aging mitigation, cardiovascular and immune homeostasis
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern